Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
The three inactive preparations showed low-frequency (2-4 c/min) rhythmic phrenic bursts when the medulla was perfused with the α2-adrenoceptor antagonist Piperoxane (50 μM; 5 min) and the pons was perfused with artificial cerebrospinal fluid (ACSF). During the final 3 minutes of piperazine application, the frequency of 12 active phrenic bursts increased significantly (163 ± 12% of the preceding mean frequency). The effects of NA administration (25 μM; 5 min) on preparations perfused with either ACSF (n = 8) or the α2-adrenoceptor antagonist Piperoxane (50 μM; PIP-ACSF; n = 5) were compared in active medullary preparations. Impact). Diaphragmatic burst frequency was shown to be significantly increased by either piperazine alone (PIP-ACSF+NA) or piperazine plus NA (NA-ACSF). Nevertheless, the augmentation of phrenic burst frequency was amplified by piperazine-induced blockade of medullary α2-adrenergic receptors: five minutes after NA application, phrenic burst frequency reached 171 ± 11% of the mean control value when ACSF was applied alone, and the average control value when PIP-ACSF was applied under 234 ±21% control conditions [1].
|
---|---|
References |
[1]. Viemari JC, et al. Nasal trigeminal inputs release the A5 inhibition received by the respiratory rhythm generator of the mouse neonate. J Neurophysiol. 2004 Feb;91(2):746-58.
[2]. Bentley GA, et al. The antinociceptive action of some beta-adrenoceptor agonists in mice. Br J Pharmacol. 1986 Jul;88(3):515-21 |
Molecular Formula |
C14H20CLNO2
|
---|---|
Molecular Weight |
269.769
|
CAS # |
135-87-5
|
Related CAS # |
59-39-2;135-87-5 (HCl);
|
SMILES |
C1CCN(CC1)CC2COC3=CC=CC=C3O2.Cl
|
Synonyms |
F933; F 933 hydrochloride; Piperoxan HCl
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~50 mg/mL (~185.34 mM)
DMSO : ≥ 31 mg/mL (~114.91 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (92.67 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.7069 mL | 18.5343 mL | 37.0686 mL | |
5 mM | 0.7414 mL | 3.7069 mL | 7.4137 mL | |
10 mM | 0.3707 mL | 1.8534 mL | 3.7069 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.